Stem Cell Technologies And Applications Will Generate $15.8bn In 2019, A New Visiongain Analysis Predicts

13 September 2018
Pharma

A new visiongain report forecasts that the worldwide stem cell technological and applications market will generate revenues of $15.8bn in 2019. That forecast and others appear in Stem Cell Technologies and Applications Market Report 2016-2026: Hype vs Reality for That Transformative Technology with Vast R&D Pipeline and Expanding Use of HSCT and Cord Blood Banking, published in November 2015. Visiongain is a business information publisher and consultancy in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Stem cells have been seen for many years as an upcoming and potentially transformative technology. In 2015, the market has yet to realise its great potential, but stem cell technologies remain on the cusp of significant market expansion. Factors such as the increasing use of hematopoietic stem cell transplantation (HSCT), the launch of current pipeline therapies and the expanding use of cord blood banking services and stem cell-based assays will stimulate this market over the next ten years.

“However the industry has many barriers to overcome. Current reimbursement and regulatory systems will need to be updated to adapt to the unique challenges posed by these non-traditional therapies. In addition, companies will have to attract the attention of Big Pharma, which sometimes remains wary of this exciting but potentially risky field.”

Visiongain’s updated analysis gives revenue forecasting to 2026 for the overall stem cell technologies and applications market. It also shows revenue predictions from 2015 to 2026 for the following five submarkets:

• Cancer treatment (oncology)
• Cardiovascular therapy
• CNS uses
• Other therapies
• Non-therapeutic applications.

The report also provides revenue forecasts to 2026 for six stem cell therapies:

• MSC-100-IV (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Evolution and Elite (Orthofix)
• CARTISTEM (MEDIPOST).

That investigation shows interviews with the Human Stem Cells Institute (HSCI), Apceth, MEDIPOST, Harvard Stem Cells Institute and the Stem Cell Program at Boston’s Children’s Hospital. It also discusses research and development, reviewing the most promising advances. The study also discusses leading companies, assessing their activities and potentials.

Stem Cell Technologies and Applications Market Report 2016-2026 adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

19 March 2019

Read

“Global Anaesthesia Drugs market set to grow to $11.8bn by 2024” says new Visiongain report

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

19 March 2019

Read

“The Global Pharma Contract Sales market will be driven by cost saving and the need for more flexibility” says new Visiongain report

With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.

28 February 2019

Read

“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.

28 February 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1